RAS(ON) Inhibitors for Colorectal and Pancreatic Cancer
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
Recruiting
Phase 1
Phase 2
Interventional Study
Colorectal Cancer
CRC
Pancreatic Ductal Adenocarcinoma
PDAC
Gastrointestinal Cancer
Metastatic Pancreatic Ductal Adenocarcinoma
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 1/2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 1,130 (estimated)
- Sponsor
- Revolution Medicines, Inc. · Industry
Who this trial is looking for
This trial is looking for adults with certain types of gastrointestinal cancer. Participants will receive new treatments combined with standard care to see how well they work and what side effects they may cause.
Are You a Good Fit for This Trial?
You may be able to join if
- I am at least 18 years old
- I have good organ function
- I have metastatic pancreatic cancer or advanced colorectal cancer
- My colorectal cancer has a specific mutation
- My overall health is good (ECOG PS 0 to 1)
You may not be able to join if
- I have primary brain tumors
- I have gastrointestinal problems that could affect treatment
- I have had major surgery in the last 28 days
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with novel agents.
The current subprotocols include the following:
Subprotocol A: RMC-6236 + 5-fluorouracil-based regimens
Subprotocol B: RMC-6236 + cetuximab with or without mFOLFOX6
Subprot…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
All Patients (unless otherwise noted):
* ≥ 18 years of age
* ECOG PS is 0 to 1
* Adequate organ function as outlined by the study
* Pathologically or cytologically documented pancreatic carcinoma or poorly differentiated pancreatic carcinoma with metastatic disease or RAS-mutat…
Contacts